Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition

Afatinib for the treatment of advanced non-small-cell lung cancer

(2014) Carlo Genova et al.   EXPERT OPINION ON PHARMACOTHERAPY

ICAM-3 endows anticancer drug resistance against microtubule-damaging agents via activation of the ICAM-3-AKT/ERK-CREB-2 pathway and blockage of apoptosis

(2013) Kwang-Chul Ahn et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

ERK1/2 Blockade Prevents Epithelial-Mesenchymal Transition in Lung Cancer Cells and Promotes Their Sensitivity to EGFR Inhibition

(2013) J. M. Buonato et al.   CANCER RESEARCH

Afatinib: First Global Approval

(2013) Rosselle T. Dungo et al.   DRUGS

Curcumin Suppresses Doxorubicin-Induced Epithelial–Mesenchymal Transition via the Inhibition of TGF-β and PI3K/AKT Signaling Pathways in Triple-Negative Breast Cancer Cells

(2013) Wei-Chih Chen et al.   JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

(2013) Chee Khoon Lee et al.   JNCI-Journal of the National Cancer Institute

Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC

(2013) Hideki Terai et al.   MOLECULAR CANCER RESEARCH

Acquisition of epithelial–mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance

(2013) L Chang et al.   Cell Death & Disease

Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

(2013) A. O. Walter et al.   Cancer Discovery

A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop

(2013) K E Ware et al.   Oncogenesis

Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locations

(2012) Woody Han et al.   CANCER LETTERS

Age-dependent accumulation of genomic aberrations and deregulation of cell cycle and telomerase genes in metastatic neuroblastoma

(2012) Simona Coco et al.   INTERNATIONAL JOURNAL OF CANCER

Identification of ALK germline mutation (3605delG) in pediatric anaplastic medulloblastoma

(2012) Simona Coco et al.   JOURNAL OF HUMAN GENETICS

The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor

(2012) Y. Kim et al.   MOLECULAR CANCER THERAPEUTICS

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

(2008) D Li et al.   ONCOGENE

The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations

(2008) A. Dubrovska et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA